Safety, tolerability, acceptability and immunogenicity of an influenza vaccine delivered to human skin by a novel high-density microprojection array patch (Nanopatch (TM))
Germain JP Fernando, Julian Hickling, Cesar M Jayashi Flores, Paul Griffin, Christopher D Anderson, S Rachel Skinner, Cristyn Davies, Katey Witham, Melinda Pryor, Jesse Bodle, Steve Rockman, Ian H Frazer, Angus H Forster
VACCINE | ELSEVIER SCI LTD | Published : 2018
BACKGROUND: Injection using needle and syringe (N&S) is the most widely used method for vaccination, but requires trained healthcare workers. Fear of needles, risk of needle-stick injury, and the need to reconstitute lyophilised vaccines, are also drawbacks. The Nanopatch (NP) is a microarray skin patch comprised of a high-density array of microprojections dry-coated with vaccine that is being developed to address these shortcomings. Here we report a randomised, partly-blinded, placebo-controlled trial that represents the first use in humans of the NP to deliver a vaccine. METHODS: Healthy volunteers were vaccinated once with one of the following: (1) NPs coated with split inactivated influe..View full abstract
Awarded by Vaxxas Pty Ltd, Brisbane, QLD, Australia
Vaxxas Pty Ltd, Brisbane, QLD 4102, Australia (ACTRN12616000880448).